Can a Saliva Test Help Detect Prostate Cancer?

A saliva test for prostate cancer can identify inherited gene changes that may raise a person's lifetime risk, but it cannot by itself diagnose prostate cancer. Diagnosis still relies on an individual assessment that may include PSA testing, examination, prostate MRI, and sometimes a biopsy.

How a Saliva Test Fits Into Prostate Cancer Care

A saliva test for prostate cancer usually looks for inherited genetic variants, also called germline mutations, linked with a higher risk of developing prostate cancer. The sample is collected by spitting into a tube or using a mouth swab, then sent to a laboratory for genetic analysis. It is simple and non-invasive, but it is not a stand-alone cancer test.

These tests may look at genes involved in DNA repair, including BRCA1, BRCA2, ATM, CHEK2, and others selected by the laboratory or clinician. A harmful inherited variant may help explain a strong family pattern of prostate, breast, ovarian, pancreatic, or related cancers. It can also help doctors recommend a more personalised plan for screening and, if cancer is diagnosed, may sometimes inform treatment choices.

A normal saliva genetic test cannot rule out prostate cancer, and a positive result does not mean that cancer is present or certain to develop. For a current concern about prostate cancer, clinicians use a combination of medical history, PSA blood testing, examination, imaging, and biopsy when needed. More information about the disease itself is available in prostate cancer information.

What Is the Newest Test for Prostate Cancer?

There is no single “newest” test that has replaced all others. Modern prostate cancer assessment increasingly combines established tools with newer risk-stratification methods. PSA blood testing remains an important first step, while multiparametric MRI has become a valuable tool for evaluating men with an elevated or changing PSA level.

Multiparametric MRI provides detailed pictures of the prostate and can identify areas that may need targeted sampling. In some people, a reassuring MRI result together with other low-risk findings may help avoid an immediate biopsy. However, MRI does not detect every cancer, so the result must be considered alongside PSA levels, PSA density, family history, examination findings, and personal risk factors.

Other tests may include blood, urine, tissue, and genetic tests designed to refine risk after an abnormal PSA result or a biopsy. Their availability and usefulness vary. A clinician can explain whether a particular test is appropriate rather than relying on one result alone.

• PSA blood test: measures prostate-specific antigen, which can rise for several reasons.
• Digital rectal examination: checks for changes in the prostate that may need further evaluation.
• Multiparametric MRI: assesses the prostate before or alongside a biopsy decision.
• Biopsy: confirms whether cancer is present and provides grading information.
• Genetic testing: evaluates inherited risk and may guide care in selected people.

PSA Results: What Should a 70 Year Old PSA Score Be?

There is no single PSA score that is “normal” for every 70-year-old. PSA levels naturally vary with age and prostate size, and they may be affected by non-cancerous enlargement of the prostate, inflammation, infection, recent ejaculation, cycling, urinary procedures, and some medicines. Laboratories may provide reference ranges, but these should not be used as a diagnosis on their own.

Doctors often focus on the overall pattern rather than one number. They may consider whether PSA has changed over time, the person’s age, family history, examination findings, prostate volume, and PSA density, which compares PSA with prostate size. A repeat PSA test may be advised when a result is unexpectedly raised, particularly if temporary influences are possible.

PSA is useful because it can help detect clinically significant prostate cancer earlier in some people, but it also has limitations. Some prostate cancers occur with lower PSA levels, while many men with a raised PSA do not have cancer. A urologist can discuss whether MRI, additional testing, or biopsy is needed based on the full clinical picture.

Why Is PSA Screening No Longer Recommended?

PSA screening has not been universally stopped. Instead, many health authorities recommend shared decision-making because the potential benefits and harms differ from person to person. Screening may find cancer early, but it can also identify slow-growing cancers that would never cause symptoms or shorten life.

When low-risk cancers are detected, some men may experience anxiety and undergo repeated tests or treatments they may not ultimately need. Treatments can sometimes affect urinary control, sexual function, or bowel function. False-positive PSA results can also lead to further testing, while false-negative results can provide false reassurance.

For these reasons, screening decisions are usually individualised. Age, life expectancy, family history, ancestry, known inherited genetic variants, previous PSA results, and personal views about testing all matter. Men considering PSA screening should discuss the possible advantages, limitations, and follow-up pathways with a qualified clinician before deciding.

How Prostate Cancer Is Confirmed and Assessed

If prostate cancer is suspected, a doctor may first repeat the PSA test and check for factors that could have temporarily affected it. A medical history and digital rectal examination may also be performed. If concern remains, multiparametric MRI is often used to assess the prostate and identify areas that require closer investigation.

A prostate biopsy is the only way to confirm a cancer diagnosis. During a biopsy, small tissue samples are taken from the prostate and examined by a pathologist. The report describes features such as the Gleason score or Grade Group, which help estimate how likely the cancer is to grow or spread.

If cancer is found, imaging may be used to determine whether it appears confined to the prostate or has spread beyond it. In selected situations, advanced imaging such as PSMA PET may be considered. These results support a risk-based treatment discussion rather than a one-size-fits-all approach.

What Is the Newest Way to Treat Prostate Cancer?

The newest way to treat prostate cancer is not one single procedure or medicine. Modern care increasingly uses precision treatment: choosing the least intensive effective option based on the cancer’s risk group, location, spread, biology, and the individual’s overall health and priorities. Newer approaches may include advanced imaging, genomic testing in selected cases, image-guided radiotherapy, robotic surgery, and targeted medicines for certain advanced cancers.

For low-risk cancer that is unlikely to cause harm in the near term, active surveillance may be recommended. This means regular PSA tests, MRI scans, examinations, and sometimes repeat biopsies, with treatment offered if the cancer shows signs of progression. It is an active management plan, not the same as ignoring the condition.

For cancer confined to the prostate, main curative options may include surgery to remove the prostate or radiotherapy. Robotic prostatectomy may be suitable for some patients, while radiotherapy treatment can be delivered using carefully planned techniques. For locally advanced or metastatic disease, treatment may include hormone therapy, chemotherapy, newer hormone-blocking medicines, targeted therapies, immunotherapy in selected circumstances, or radioligand therapy where appropriate.

Each option has possible benefits and side effects. Decisions should be made with a multidisciplinary team and should account for urinary, sexual, and bowel health as well as cancer control. Supportive care, rehabilitation, and follow-up remain important at every stage.

Who May Benefit From Genetic Testing and Earlier Assessment?

Genetic counselling and saliva-based testing may be considered for men with prostate cancer that is advanced, metastatic, high-risk, or diagnosed at a relatively young age. It may also be appropriate when there is a notable family history of prostate cancer or related cancers, particularly breast, ovarian, pancreatic, or male breast cancer.

Before testing, genetic counselling can help a person understand what results may mean for them and their relatives. A positive result can influence screening plans for family members, but it may also have emotional and practical implications. A genetics professional can explain the limits of testing and discuss informed consent.

Men without known cancer may benefit from earlier conversations about PSA screening if they have a father, brother, or multiple relatives with prostate cancer, especially when diagnoses occurred at a younger age. The timing and frequency of assessment should be decided individually with a healthcare professional.

When to Seek Medical Care

A person should arrange a medical assessment if they have persistent urinary symptoms, such as difficulty starting urination, a weak stream, frequent urination, waking often at night to urinate, pain when passing urine, or blood in the urine or semen. These symptoms are common and are often caused by non-cancerous conditions, but they should still be evaluated.

Prompt medical advice is important for new bone pain that persists, unexplained weight loss, marked fatigue, or urinary retention, particularly in someone with a history of prostate cancer. Sudden inability to pass urine requires urgent assessment.

People with a strong family history of prostate cancer or known inherited cancer-related gene changes can ask their doctor whether earlier risk assessment, PSA testing, genetic counselling, or specialist referral is appropriate. Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals support diagnosis and treatment planning for international patients.

Frequently asked questions